- Home
- JBGS vs JANX Comparison
JBGS vs JANX Comparison
Compare JBGS & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JBGS | JANX |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 906.3M | 790.3M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | JBGS | JANX |
|---|---|---|
| Price | $14.79 | $14.31 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 1 | 13 |
| Target Price | $15.00 | ★ $47.00 |
| AVG Volume (30 Days) | 436.5K | ★ 936.8K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.69% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $498,598,000.00 | $10,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.03 | $12.12 |
| 52 Week High | $24.30 | $35.34 |
Technical Indicators
Market Signals| Indicator | JBGS | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 43.97 | 45.38 |
| Support Level | $14.09 | $13.10 |
| Resistance Level | $16.04 | $14.44 |
| Average True Range (ATR) | 0.37 | 0.61 |
| MACD | -0.04 | -0.16 |
| Stochastic Oscillator | 6.43 | 14.80 |
Price Performance
Historical ComparisonAbout JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party real estate services. It generates maximum revenue from the commercial segment.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.